Safety, pharmacodynamics and pharmacokinetics of a novel JAK1-selective inhibitor, IN-115314, in healthy participants: A first-in-human study.
AIMS Selective JAK1 inhibition can control inflammation in immune-mediated diseases with reduced haematological toxicity. IN-115314, a selective JAK1 inhibitor, was evaluated in a first-in-human, randomized, double-blind, placebo-controlled study in healthy participants for safety, pharmacokinetics (PK) and pharmacodyn...